Sangamo Therapeutics stands at a pivotal moment this Thursday as the gene therapy specialist prepares to release quarterly financial results that could determine the company’s future trajectory. With shares languishing at $0.58 and the company’s stock exchange listing under threat, today’s earnings report may prove decisive for the struggling biopharmaceutical firm.
Financial Performance Under Scrutiny
Market expectations for the third quarter of 2025 remain exceptionally low, with analysts projecting a loss of $0.10 per share. This represents a significant deterioration compared to the same period last year. The revenue picture appears even more challenging, with forecasts indicating only $34.4 million in revenue—a dramatic 30% decline from the previous $49.4 million and clear evidence of the company’s current operational difficulties.
The substantial revenue drop stems from recent strategic shifts within the organization. While Sangamo’s collaboration with Pfizer for hemophilia A therapy dissolved, the company secured an agreement with Eli Lilly that brought an immediate $18 million payment and potential future milestones totaling $1.4 billion. This new partnership focuses primarily on neurological disorders, though questions remain about whether this strategic pivot will prove sufficient.
Should investors sell immediately? Or is it worth buying Sangamo Therapeutics?
Regulatory Progress and Pipeline Potential
Investor attention remains fixed on ST-920, Sangamo’s gene therapy candidate for Fabry disease, which represents the company’s most promising asset. The therapy received FDA clearance for an accelerated approval pathway that could potentially shorten the regulatory timeline by up to three years. Company leadership plans to submit the biologics license application in early 2026, with commercial launch potentially following later that same year if approved.
Exchange Listing Concerns Intensify
The most immediate challenge, however, involves maintaining the company’s NASDAQ listing. Since October, Sangamo has faced the threat of delisting after its stock price remained below the $1 threshold for 30 consecutive trading days. The company had until October 27 to regain compliance, but with shares trading at $0.58, achieving this goal appears increasingly difficult.
Today’s earnings conference call represents a critical opportunity for management to outline their strategy for reversing the company’s fortunes. Financial analysts remain divided on Sangamo’s prospects, with some maintaining price targets as high as $5.29 while others recommend holding positions with targets around $4.50. The quarterly results will indicate whether management can articulate a credible turnaround plan or if the downward trend will continue unabated.
Ad
Sangamo Therapeutics Stock: Buy or Sell?! New Sangamo Therapeutics Analysis from November 5 delivers the answer:
The latest Sangamo Therapeutics figures speak for themselves: Urgent action needed for Sangamo Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 5.
Sangamo Therapeutics: Buy or sell? Read more here...
